#6 - Humanigen (NASDAQ:HGEN)
Humanigen (NYSE:HGEN) is a small-cap that may be flying under your radar. It shouldn’t be anymore. As scientists have come to learn more about the novel coronavirus, it is clear that it is important to avoid patients having a cytokine storm. This is basically the body having an aggressive inflammatory response to the novel coronavirus.
Humanigen has a drug candidate, lenzilumab, which is focused on preventing such events from happening. With President Trump’s diagnosis putting cytokine storm in the headlines, the company is initiating a public stock offering of 8 million shares of common stock. The offering is being underwritten by JP Morgan Chase (NYSE:JPM) and Jefferies (NYSE:JEF). The company says it will use the funds, in part, to support the manufacturing, product, and commercial preparation of the drug.
HGEN stock is up over 500% for the year but was up even higher. In early July, the stock was up over 1,000%. It’s obviously come down with more talk of a vaccine, but the stock is up nearly 50% in the last month.
About Humanigen
Humanigen, Inc, a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.
Read More - Current Price
- $0.00
- Consensus Rating
- N/A
- Ratings Breakdown
- 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- N/A
